Curcumin and paclitaxel induce cell death in breast cancer cell lines

Abstract

Breast cancer is one of the major health issues confronting women; however, treatment with conventional chemotherapeutic drugs is limited. Currently, paclitaxel is used as a therapeutic clinical agent to treat breast cancer that exerts antitumor activity in numerous types of cancer cell. Curcumin (diferuloylmethane), a polyphenol derived from turmeric (Curcuma longa), possesses several properties that could enable it to exert an anticancer effect. Previous reports have demonstrated the synergistic effects of several chemotherapeutic drugs in combination with curcumin. Therefore, the aim of the current study was to evaluate cell death induced by curcumin and paclitaxel alone and in combination in human breast cancer cell lines: MCF7, an epithelial and luminal-like adenocarcinoma cell line triple positive for estrogen and progesterone receptor, and MDA-MB-234, a metastatic human breast cancer cell line triple negative for such receptors, as well as MCF-10F as a normal breast cell line. The results indicated that curcumin and paclitaxel induced apoptosis and necrosis, which was demonstrated through multiple methods, including assays of caspase-3/7 activity, Annexin V, poly(ADP-ribose) polymerase-1 activation and protein expression of caspase-3, nuclear factor (NF)-κB transcription factor and proliferating cell nuclear antigen. The results identified that the combination of curcumin and paclitaxel had a decreased effect on apoptosis in the malignant MDA-MB-231 cell line compared with in MCF7 or MCF-10F. It was demonstrated that the combined treatment with curcumin and paclitaxel resulted in a higher level of apoptosis compared with either substance alone in breast cancer cell lines. Therefore, breast cancer treatment may benefit from the use of a combination of drugs in chemotherapy.

Curcumin- and Piperine-Loaded Emulsomes as Combinational Treatment Approach Enhance the Anticancer Activity of Curcumin on HCT116 Colorectal Cancer Model

“…Behaving synergistically, the second agent enhances the curcumin's anti-cancer activity. Doxorubicin (Zhao et al, 2015;Lv et al, 2016;Dash and Konkimalla, 2017a); docetaxel (Bayet-Robert et al, 2010;Yan et al, 2016); gemcitabine (Dhillon et al, 2008;Epelbaum et al, 2010;Kanai et al, 2011), celebrex (Lev-Ari et al, 2005;Abdallah et al, 2018), paclitaxel (Ganta and Amiji, 2009;Boztas et al, 2013;Abouzeid et al, 2014;Sarisozen et al, 2014;Kim et al, 2016;Yang et al, 2017;Calaf et al, 2018), campthotecin (Xiao et al, 2015), cisplatin (Li et al, 2017), resveratrol (Du et al, 2013), epigallocatechin gallate (EGCG) (Vivar-Quintana et al, 2006;Jin et al, 2017), sulforaphane (Danafar et al, 2018) and piperine (Shaikh et al, 2009;Kakarala et al, 2010;Patial et al, 2015;Vecchione et al, 2016;Tang et al, 2017;Baspinar et al, 2018) are among the active molecules studied in combination with curcumin for their synergistic anticancer behavior.…”

Variables pre-analíticas en los análisis de gasometría sanguínea en una institución hospitalaria de tercer nivel, Cali-Colombia

“…La presencia de burbujas de aire en las muestras también afecta la calidad de los resultados de la PO2 y pH. Calaf y Giner (32) , llevaron a cabo un estudio para valorar la calidad de cinco equipos de extracción de sangre arterial, los resultados permitieron concluir que dos de los cinco equipos valorados permitían obtener muestras con menos burbujas y mayor facilidad para eliminarlas en el 44% de los casos. Esta variable fue considerada en este estudio, puesto que se evidenció la práctica de solicitar las jeringas herparinizadas a los familiares de los pacientes hospitalizados en las unidades fuentes de información, sin embargo, no fue posible recolectar el dato.…”

“…Esto representa una debilidad en el estudio y una oportunidad para considerar en investigaciones futuras. Lima-Oliveira et al, (33) , así como Calaf y Giner (32) , evaluaron cuatro tipos de jeringas, concluyendo que existían diferencias significativas entre los…”

Artichoke Polyphenols Sensitize Human Breast Cancer Cells to Chemotherapeutic Drugs via a ROS-Mediated Downregulation of Flap Endonuclease 1

“…To further characterize the decreased cell viability induced by cotreatment, we evaluated the expression of cleaved PARP (c-PARP) and LC3 as potential molecular signs of regulated cell death. No significant modulation of these proteins was detected compared to PTX treatment alone, which is well known to cause marked cell death [52,53]. These slight effects that were detected demonstrate that both apoptotic and autophagic cell deaths are not relevant for the synergistic response of the combined treatment (Fig.…”